UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 6, 2017

ANTRIABIO, INC.

(Name of registrant in its charter)

Delaware	**000-54495**	**27-3440894**
(State or jurisdiction of incorporation or organization)	(Commission File Number)	(IRS Employer Identification No.)

1450 Infinite Drive
Louisville, CO 80027
(Address of principal executive offices)

(303) 222-2128
(Registrant's telephone number)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement

On December 6, 2017, AntriaBio, Inc. (the "**Company**" or "**we**") entered into a License Agreement ("**License Agreement** ") with XOMA LLC ("**XOMA**") pursuant to which the Company acquired the exclusive rights to develop and commercialize XOMA 358 (now RZ358) for an orphan indication, Congenital Hyperinsulinism. The Company and XOMA also entered into a Common Stock Purchase Agreement ("**Purchase Agreement**") in connection with the License Agreement (collectively, the License Agreement and the Purchase Agreement may be hereinafter referred to as the ("**Transaction Documents**").

Under the terms of the License Agreement, the Company is responsible for all development, regulatory, manufacturing and commercialization activities associated with RZ358. Pursuant to the Transaction Documents, the Company is required to pay XOMA $6 million and to issue XOMA $12 million of the Company's common stock based upon the Company's financing activities in 2018. Under the License Agreement, the Company is also required to make certain clinical, regulatory and annual net sales milestone payments of up to $222 million in the aggregate. The Company is also obliged to pay XOMA royalties ranging from the high single digits to the mid-teens based upon annual net sales of RZ358. Finally, under the terms of the License Agreement, the Company is required to pay XOMA a low single digit royalty on sales of the Company's other products.

Item 3.02 Unregistered Sales of Equity Securities

The information disclosed in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02. The issuance of the Shares have been determined to be exempt from registration under the Act in reliance on Section 4(a)(2) thereof as a transaction by an issuer not involving a public offering, in which the investor is accredited and has acquired the securities for investment purposes only and not with a view to or for sale in connection with any distribution thereof. Such securities may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Changes in Fiscal Year.

On December 7, 2017, the Company filed a Certificate of Ownership and Merger with the Secretary of State of Delaware to effectuate a merger whereby the Company would merge with its wholly-owned subsidiary, Rezolute, Inc., through a parent/subsidiary merger, with the Company as the surviving corporation. This merger, which will become effective on December 18, 2017 (the "**Effective Time**"), as pursuant to Section 253 of the General Corporation Law of Delaware. Shareholder approval for this merger was not required under Section 253 of the General Corporation Law of Delaware. Upon the Effective Time of this merger, the Company's name will change to "Rezolute, Inc." and the Registrant's Articles of Incorporation will be amended to reflect this name change. In connection with the name change, the company anticipates that its CUSIP number and trading symbol will be changed. Upon issuance of its new CUSIP number and trading symbol, the company will file an additional Current Report on Form 8-K. The Company has also filed an issuer company relation action notification with the Financial Industry Regulatory Authority.

A copy of the Articles of Merger and Agreement and Plan of Merger as filed herewith as Exhibit 2.1 and is incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

On December 7, 2017, we issued the press release attached hereto as Exhibit 99.1 and a shareholder letter attached hereto as Exhibit 99.2. In accordance with General Instruction B.2 of Form 8-K, the information set forth herein and in the press release is deemed to be "furnished" and shall not be deemed to be "filed" for purposes of the Securities Exchange Act of 1934, as amended. The information set forth in Item 7.01 of this Current Report on Form 8-K shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.

Item 9.01 Financial Statements and Exhibits

EXHIBIT	DESCRIPTION
2.1	Certificate of Ownership and Merger
99.1	Press Release of Antriabio, Inc. dated December 6, 2017*
99.2	Shareholder Letter of AntriaBio, Inc. dated December 6, 2017*

* The following exhibit relating to Item 7.01 is intended to be furnished to, not filed with, the SEC pursuant to Regulation FD.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANTRIABIO, INC.

DATE: December 7, 2017

By: /s/ Nevan Elam
Nevan Elam
Chief Executive Officer & Chairman of the Board

EXHIBIT INDEX

EXHIBIT	DESCRIPTION
2.1	Certificate of Ownership and Merger
99.1	Press Release of Antriabio, Inc. dated December 6, 2017*
99.2	Shareholder Letter of AntriaBio, Inc. dated December 6, 2017*

* The following exhibit relating to Item 7.01 is intended to be furnished to, not filed with, the SEC pursuant to Regulation FD.

Exhibit 2.1

CERTIFICATE OF OWNERSHIP AND MERGER

MERGING

REZOLUTE, INC.
(a Delaware corporation)

INTO

ANTRIABIO, INC.
(a Delaware corporation)

AntriaBio, Inc., a Delaware corporation (the "Company"), in accordance with Section 253 of the Delaware General Corporation Law, does hereby certify as follows:

1. The Company is incorporated pursuant to the laws of the Delaware General Corporation Law.

2. The Company owns all of the outstanding shares of common stock of Rezolute, Inc., a Delaware corporation (the "Subsidiary"). The Subsidiary has no shares of any other class or series of stock outstanding.

3. The Company, by the following resolutions of its Board of Directors, duly adopted on December 2, 2017, determined to merge into itself the Subsidiary on the conditions set forth in such resolutions:

WHEREAS, this Board of Directors desires to approve the merger of Rezolute, Inc., a wholly-owned Delaware subsidiary of the Company (the "Subsidiary"), with and into the Company and establish the terms and conditions of such merger in accordance with the provisions of Section 253 of the Delaware General Corporation Law;

NOW BE IT, RESOLVED, that the merger of the Subsidiary with and into the Company pursuant to the provisions of Section 253 of the Delaware General Corporation Law and the provisions set forth below is hereby approved.

RESOLVED, that, on the date that is ten (10) calendar days from the date a Certificate of Ownership and Merger is filed with the Delaware Secretary of State (the "Effective Date"), the identity, existence, purposes, powers, objects, franchises, privileges, rights and immunities of the Company shall continue in effect and unimpaired by the merger, and the corporate franchises, existence and rights of the Subsidiary shall be merged into the Company and the Company shall, as the surviving corporation, be fully vested therewith; and, further, that the separate existence and corporate organization of the subsidiary, except as they may continue by statute, shall cease of the Effective Date.

RESOLVED, that, as of the Effective Date, all shares of the Subsidiary's Common Stock held by the Company shall be cancelled.

RESOLVED, that the Certificate of Incorporation of the Company shall continue to be the Certificate of Incorporation of the Company as the surviving corporation and shall remain in effect until it shall be amended or altered in accordance with the provisions thereof; provided, however, that Article I of such Certificate of Incorporation shall be amended to read as follows:

"FIRST: The Name of the Corporation is Rezolute, Inc."

RESOLVED, that the officers of the Company are hereby authorized and directed to execute a Certificate of Ownership and Merger in accordance with the terms set forth in these resolutions and to file, or tender for filing, and record and take such other action as may be necessary to effectuate the merger and the actions contemplated hereby in any and all jurisdictions where such filing, recording or other action shall be required.

4. The Certificate of Ownership and Merger shall be effective on December 18, 2017.

IN WITNESS WHEREOF, the undersigned has signed his name and affirmed that this instrument is the act and deed of the Company and that the statements herein are true, under penalties of perjury, this 6th day of December, 2017.

[The remainder of this page is intentionally left blank.]

ANTRIABIO, INC.,
a Delaware corporation

By: /s/ Nevan Elam
Name: Nevan Elam
Title: Chief Executive Officer

Exhibit 99.1

AntriaBio Announces Exclusive License Agreement for a Phase 2 Orphan Disease Therapy with XOMA Corporation and Name Change to Rezolute, Inc.

LOUISVILLE, Colorado, December 7, 2017 – (GLOBE NEWSWIRE) – Rezolute, Inc. ("Rezolute" or the "Company") (OTCQB: ANTB), a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies for metabolic and orphan diseases, and **XOMA Corporation ("XOMA") (NASDAQ: XOMA)**, a pioneer in the discovery, development and licensing of therapeutic antibodies, announced today that they have executed a license agreement that provides Rezolute with the exclusive global rights to develop and commercialize RZ358 (formerly XOMA 358) for Congenital Hyperinsulinism (CHI), an ultra-orphan indication.

RZ358 is a first-in-class fully human monoclonal antibody that counteracts the effects of elevated insulin via allosteric modulation of the insulin receptor, making it well-suited as a therapy for severe, persistent hypoglycemia caused by hyperinsulinemic conditions such as CHI. XOMA demonstrated clinical proof-of-concept through Phase 2a studies and Rezolute plans to advance clinical development in 2018. The compound has received designated orphan status in the US and European Union.

"We are excited about the addition of RZ358 to our growing product pipeline and for the opportunity to take a Phase 2 program forward with the hope of being able to offer a significantly better treatment option for a disease that is the most frequent cause of severe, persistent hypoglycemia in newborn babies and children," said Nevan Elam, Chairman and Chief Executive Officer of Rezolute. "XOMA has generated compelling safety data and proof-of-concept for RZ358 and we look forward to advancing its development."

Under the terms of the agreement, Rezolute will assume the global development, regulatory filings, manufacturing and commercialization for RZ358. In turn, XOMA will receive a total of $18 million in the form of cash and shares of Rezolute common stock and will be eligible to receive up to an aggregate of $222 million in clinical, regulatory and sales milestones. In addition, XOMA is entitled to receive royalties ranging from the high single digits to the mid-teens based upon annual net sales of RZ358. Finally, under the terms of the agreement, Rezolute will pay XOMA low single digit royalties on sales of the company's other products.

"Having established proof-of-concept for XOMA 358 earlier this year, we look forward to Rezolute continuing clinical development of the program," stated Jim Neal, Chief Executive Officer of XOMA. "Our license agreement with Rezolute places this important drug asset in the hands of a very capable endocrine-focused team, provides XOMA with the potential to receive future milestones and royalties, and is an important milestone in the continued transformation of our programs to fully-funded status. We welcome Rezolute to our broad portfolio of partners, including Novartis, Five Prime and NanoTherapeutics, who continue the development of our product candidates."

CHI is a rare genetic disorder that affects one in 50,000 newborns. Ordinarily, beta cells in the pancreas secrete just enough insulin to keep blood sugar in the normal range. With CHI, the secretion of insulin is not properly regulated as the beta cells secrete too much insulin resulting in excessive low blood sugar (severe hypoglycemia). In infants and young children, these episodes are characterized by lethargy, irritability and difficulty feeding. Repeated episodes of hypoglycemia increase the risk of serious complications such as breathing difficulties, seizures, developmental delays and intellectual disability, vision loss, brain damage, coma and possibly death. CHI is the most common cause of persistent hypoglycemia in children and about 60 percent of infants with CHI experience a hypoglycemic episode within the first month of life. Other affected children develop hypoglycemia by early childhood. A significant number of patients cannot be adequately treated with or do not tolerate existing medical therapies. Surgical removal of all or part of the pancreas is a cornerstone of management for many patients, but is invasive and diabetes-inducing.

The Company's new name reflects its transition as a developer of potentially paradigm-shifting therapies for treating metabolic diseases and orphan indications with high unmet medical needs. Under this strategy, the Company also exclusively licensed ActiveSite Pharmaceuticals' oral plasma kallikrein inhibitor (PKI) portfolio in August and is developing RZ402 for Diabetic Macular Edema and RZ602 for Hereditary Angioedema, an orphan indication.

"The name change conveys our dedication to identifying and developing therapies that are transformative and target well-known genetic pathways and mechanisms," stated Mr. Elam. With the recent licensing agreements executed with XOMA Corporation for a monoclonal antibody to treat CHI, an orphan indication, and ActiveSite Pharmaceuticals for our oral Plasma Kallikrein Inhibitor (PKI) portfolio, we have evolved into a company advancing a robust pipeline of innovative solutions for patients and providers."

About Rezolute, Inc.
Rezolute is a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies to improve the lives of patients with metabolic and orphan diseases. Rezolute is advancing a diversified pipeline including: RZ358 (Phase 2), an antibody for the ultra-orphan indication of Congenital HyperInsulinism (CHI), with an abbreviated path-to-market strategy; AB101 (Phase 1), a once-weekly injectable basal insulin with the potential to transform the treatment landscape in diabetes management by reducing the therapeutic burden for patients and improving compliance; and a Plasma Kallikrein Inhibitor (PKI) portfolio with two lead compounds, RZ402 (plan to file IND in H2 2018) targeting Diabetic Macular Edema (DME) and RZ602 (plan to file IND in H1 2019) targeting Hereditary Angioedema (HAE), an orphan indication. For more information, visit: www.rezolutebio.com.

About XOMA Corporation
XOMA has an extensive portfolio of products, programs, and technologies that are the subject of licenses the Company has in place with other biotech and pharmaceutical companies. Many of these licenses are the result of the Company's pioneering efforts in the discovery and development of antibody therapeutics. There are more than two dozen such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. For more information, visit www.xoma.com.

Forward-Looking Statements
This release, like many written and oral communications presented by Rezolute, Inc. and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of the Company, are generally identified by use of words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.

Rezolute, Inc. Contact:
Noopur Liffick
VP of Corporate Development
(650) 549-4175
investor-relations@rezolutebio.com

Source: Rezolute, Inc.

Exhibit 99.2

A Letter From The Chairman & CEO

Dear Colleagues, Shareholders and Friends:

Today we issued a press release announcing our agreement with XOMA Corporation to in-license RZ358, a Phase 2 antibody to treat Congenital Hyperinsulinism (CHI), an ultra-orphan metabolic disease. With the addition of this program to our product pipeline, we have achieved a significant milestone in our corporate evolution, and the purpose of this letter is to update you on our go-forward plans as well as the status of the business.

In my 2016 letter to shareholders, I highlighted our belief in the importance of advancing our microsphere platform while opportunistically seeking to in-license or acquire external programs and capabilities that could facilitate the creation of a robust, high-value biopharmaceutical company. Our corporate development activities this year reflect the implementation of that strategy. We believe the best way to increase shareholder value and unlock the possibility of up-listing onto a national stock exchange with the support of institutional investors is to advance multiple pipeline programs at different stages across different platforms. I am happy to inform you that we now have four active programs across three platforms including: (i) a Phase 2 antibody (RZ358), (ii) a Phase 1 microsphere (AB101), and (iii) two preclinical oral plasma kallikrein inhibitors (RZ402 and RZ602).

In just a few months we have transformed the company from a microsphere-based diabetes organization to a clinical stage metabolic and orphan disease company with a portfolio of potentially paradigm-shifting therapies for patients and providers. “AntriaBio” is and will remain known as the microsphere company developing a long-acting insulin. With the broadening of our capabilities, programs and mission, we are emphasizing our new mandate. By changing the company’s name to “Rezolute,” we are resolved to apply different technologies and modalities to develop transformative therapies for diseases with high unmet needs.

RZ358

CHI is a rare genetic disorder that affects 1 in 50,000 newborns. Ordinarily, beta cells in the pancreas secrete just enough insulin to keep blood sugar in the normal range. With CHI, the secretion of insulin is not properly regulated as the beta cells secrete too much insulin resulting in excessive low blood sugar (severe hypoglycemia). In infants and young children, these episodes are characterized by lethargy, irritability and difficulty feeding. Repeated episodes of hypoglycemia increase the risk of serious complications such as breathing difficulties, seizures, developmental delays and intellectual disability, vision loss, brain damage, coma and possibly death. CHI is the most common cause of persistent hypoglycemia in children and about 60 percent of infants with CHI experience a hypoglycemic episode within the first month of life. Other affected children develop hypoglycemia by early childhood.

To avoid hypoglycemia, many children require frequent glucose monitoring and feeding, including intravenous or intestinal administration of sugar solutions, particularly overnight. This burdensome treatment regimen has a substantially negative effect on the quality of life for these children and their families. In addition, a significant number of children cannot be adequately treated with, or do not tolerate, existing medical therapies. Surgical removal of all or part of the pancreas is a cornerstone of management for many children, but is invasive and diabetes-inducing.

1450 Infinite Drive, Louisville, CO 80027
P: 303.222.2128
www.rezolutebio.com

RZ358 is a first-in-class fully human monoclonal antibody that counteracts the effects of elevated insulin (hyperinsulinemia) by, in effect, turning down the insulin receptor when too much insulin is present, making it well-suited as a treatment for severe, persistent hypoglycemia. XOMA demonstrated clinical proof-of-concept for RZ358 in Phase 2a studies and the compound has designated orphan status in the US and EU. We are preparing to launch Phase 2b studies in 2018 with the potential to accelerate late-stage pivotal trials for an abbreviated path-to-market strategy.

AB101

As a prerequisite to engaging in our corporate development/in-licensing activities, we first wanted to realize the objective that was the basis for the formation of AntriaBio. The primary reason most of us invested our time, energy and money was to advance AB101, a once-weekly injectable basal insulin for patients with diabetes, into the clinic as a potential disruptive therapy in the $11 billion basal insulin market that is still dominated by insulin analogs administered by daily injections.

A year ago, we set a corporate goal to complete a successful manufacturing campaign, file an investigational new drug application (IND) with the US Food & Drug Application (FDA) and start our Phase 1 first-in-human clinical study of AB101, all by the middle of 2017. In fact, we achieved each of these objectives: we produced sterile AB101 material in the first half of 2017; we filed our IND in June; and we recently completed the first of up to five potential cohorts in the AB101 clinical study being conducted at ProSciento, a contract research organization in Southern California. We look forward to dosing the next cohort in the new year, with the goal of demonstrating that the pharmacological profile of AB101 lasts for more than a week while meaningfully lowering glucose levels.

PKI Portfolio

In August of this year, soon after initiating our first-in-human study of AB101, we took the first step in realizing our corporate development objectives by in-licensing ActiveSite Pharmaceuticals' oral plasma kallikrein inhibitor (PKI) portfolio. In our evaluation of the PKI portfolio, we became increasingly convinced of its potential to address serious diseases. Further, we believe the PKI portfolio may be the most advanced oral program in the space, given the extensive preclinical work previously conducted, including not only *in vitro* modeling, but also *in vivo* studies in the rodent, dog and monkey.

Plasma kallikrein is an enzyme that is part of the kinin system, which is a complex metabolic cascade that can play a prominent role in inflammation. Specifically, plasma kallikrein ultimately contributes to the production of a peptide called bradykinin, which causes blood vessels to enlarge or dilate, resulting in problematic inflammation and vascular leakage. By inhibiting the formation of plasma kallikrein and the subsequent production of bradykinin, we believe we may be able to treat metabolic and orphan diseases associated with vascular leakage. For example, diabetic macular edema (DME) and hereditary angioedema (HAE) are two diseases that are impacted by the kinin system that could potentially benefit from an oral PKI.

RZ402

DME is a metabolic disease that results from an increase in retinal vascular permeability (RVP) in the setting of diabetic retinopathy (abnormal retinal blood vessel growth caused by poorly controlled blood sugar levels). Vascular leakage from retinal blood vessels leads to swelling of the retina, including the macula, an area of the retina that is very important for vision. The kinin system and the production of bradykinin have been implicated in the vascular leakage associated with DME. It is estimated that approximately 50 million individuals worldwide suffer from vision-threatening complications of diabetes, including DME, which is one of the main causes of vision loss in working-age adults globally. With the growth of diabetes, DME is expected to increase in prevalence beyond its current estimate of 750,000 individuals in the US and 21 million worldwide.

Current treatment approaches are onerous, involving injections into the eye by retinal specialists on a monthly or bimonthly basis. In addition to a segment of the DME population that does not respond to these treatments, the extent of therapeutic benefit directly correlates with adherence to this route of administration and regimen, which is a significant burden for both patients and their healthcare providers, leading to high rates of non-adherence and ultimately, suboptimal therapeutic outcomes.

RZ402 is a potential new therapy for DME from the PKI portfolio. RZ402 has been shown to normalize RVP in clinically-relevant animal models of macular edema as effectively as the current injectable treatments, thereby supporting its potential as a stand-alone therapy for macular edema resulting from diabetes and other causes. We are planning to file an IND for RZ402 in the second half of 2018.

RZ602

HAE is an orphan disease characterized by recurring attacks of sudden and extreme swelling that can affect the face and mucous membranes, abdomen and genitalia. Attacks can be painful, debilitating, varied in frequency and even life-threatening, due to swelling around the airway. The disease is caused by a problem with a gene that controls the management of a specific protein, the C1 inhibitor. When there is an imbalance in the C1 inhibitor, there may be excessive bradykinin production causing tiny blood vessels to “leak” or push fluid into parts of the patient’s body, resulting in an HAE attack. The trigger for an attack is variable from person to person and even time to time.

Currently available therapies target the prevention or termination of attacks, but are highly invasive and inconvenient due to the subcutaneous/intravenous routes of administration or have an undesirable side effect profile. Approximately one in 50,000 patients worldwide have HAE.

RZ602 is a potential new therapy for HAE from the PKI portfolio. Similar to our efforts with RZ402 for DME, the objective of RZ602 is to stop the inflammatory cascade by inhibiting the production of kallikrein and thereby halting the downstream release of bradykinin and eventual swelling. We plan to file an IND for RZ602 in the first half of 2019.

Notably, in October of this year, one of our competitors, KalVista, announced a transaction with Merck whereby Merck agreed to pay KalVista $37 million up front and up to $715 million in milestone payments for an intravitreal (injection into the eye) PKI currently in Phase 2, as well as other potential preclinical oral PKIs for DME. Merck also agreed to take a 10% equity stake in KalVista with a $9 million investment. We believe this transaction validates the potential utility of the kallikrein pathway in treating certain diseases.

Other Pipeline Activities

Our research scientists are actively leveraging our multiple platform technologies to formulate new compounds, conduct studies and screen potential new product candidates as we seek to evolve our product pipeline.

Expansion of our Board of Directors and Scientific Advisory Board

In preparation for a potential up-listing to a national exchange in 2018, this year we added several new members to our Board of Directors (Board) and implemented certain governance requirements, including the creation of various Board committees. In October, we announced our newest Board member, Gil Labrucherie, who is Chief Financial Officer of Nektar Therapeutics, a biopharmaceutical company. In March, two other pharmaceutical executives joined the Board, including Tae Hoon Kim and Samir R. Patel, M.D. Mr. Kim is currently Chief Executive Officer of Aju Pharm, a pharmaceutical company in the Republic of Korea and Dr. Patel is co-founder, principal and former CEO of SPEC Pharma, LLC. Finally, in October Dr. Robert Bhisitkul joined our Scientific Advisory Board and he is a retinal specialist and Professor of Clinical Ophthalmology at the University of California, San Francisco School of Medicine. His expertise in DME drug development will be invaluable as we advance RZ402 into the clinic.

Capital Requirements and Effect of Name Change

Given our current financial needs as well as our desired strategy to advance our product pipeline candidates, we are planning to raise capital in the first half of 2018, primarily from institutional investors. We anticipate our capital-raising activities may include the issuance of equity or debt securities, obtaining credit facilities or other financing mechanisms. Clearly, if we are unable to raise capital, our prospects will be materially and adversely impacted.

The Company's name change does not affect our corporate structure. The rights of stockholders holding certificated shares under currently outstanding stock certificates and the number of shares represented by those certificates will remain unchanged. The name change does not affect the validity or transferability of any currently outstanding stock certificates nor will it be necessary for stockholders with certificated shares to surrender any stock certificates they currently hold as a result.

Closing

We hope you share in our excitement about today's announcement regarding RZ358 and our evolution as a company. With the addition of RZ358 as well as RZ402 and RZ602, we have "more shots on goal" with a diversification strategy centered around metabolic and orphan diseases. We are not dependent upon any single pipeline candidate for success. Through our corporate development activities, we have significantly increased the value and attractiveness of the company. I am particularly pleased we have been able to accomplish the in-licensing of RZ358 and the PKI portfolio with only $750,000 in upfront cash and minimal dilution. This is a phenomenal achievement and virtually unprecedented in our industry.

In 2018, we have the following five primary goals:

(1) raise capital and up-list onto a national exchange;
(2) prepare for and initiate a Phase 2b study of RZ358;
(3) complete our ongoing Phase 1 study of AB101;
(4) complete the requisite preclinical work and file an IND for RZ402; and
(5) name one project currently in discovery as a pipeline candidate based upon *in vivo* studies.

I encourage you to visit our revised website and review our new corporate presentation with more information about our programs.

In closing, I would like to thank all of our stakeholders, particularly our investors, for their patience and taking a long-term view of our potential as a high-value biopharmaceutical company. We believe the steps we have taken this year to evolve the company have significantly contributed to shareholder value. We are resolved to push forward in 2018 – we are *Rezolute*!

With warm regards,

Nevan C. Elam
Chairman and Chief Executive Officer

Forward-Looking Statements

This shareholder letter, like many written and oral communications presented by AntriaBio, Inc. and Rezolute, Inc. (the “Company”), and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of the Company, are generally identified by use of words "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this letter. Except as required by applicable law or regulation, the Company undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.